Stifel Nicolaus Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Equities research analysts at Stifel Nicolaus started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $45.00 price target on the stock. Stifel Nicolaus’ target price points to a potential upside of 62.10% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Jones Trading initiated coverage on shares of Palvella Therapeutics in a report on Tuesday. They issued a “buy” rating and a $45.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. TD Cowen began coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $43.50.

Palvella Therapeutics Stock Down 0.6 %

Shares of NASDAQ:PVLA opened at $27.76 on Wednesday. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27. The stock has a market cap of $311.49 million, a P/E ratio of -2.29 and a beta of 0.54. The business’s 50 day moving average is $19.95.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PVLA. BML Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the 4th quarter valued at approximately $506,000. Geode Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter worth $171,000. ADAR1 Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter worth $1,736,000. Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics in the fourth quarter valued at $256,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Palvella Therapeutics during the 4th quarter worth $3,001,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.